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Abstract
The implication of the let-7 family in cancer development is multifaceted. The family acts as
tumor suppressor miRNA although overexpression of let-7 has also been described in many
types of cancer, including head and neck squamous cell carcinoma (HNSCC). The aim of
this study includes whether different expression levels of let-7d has an influence on chemo-
and radiosensitivity. FaDu cell line models with a gradually increased level of let-7d (models
from A to E) were generated with the lentiviral system. Expression levels of pluripotency,
chemo-radioresistance/apoptosis, and targets of mRNAs were analyzed by real-time
reverse transcription-PCR (qRT-PCR). Radiosensitivity was analyzed using a clonogenic
assay after irradiation. Response to cisplatin, 5-FU, doxorubicin, and paclitaxel was done
with MTT assay. Statistically significant decrease of K-RAS (p = 0.0369) and CASPASE3
(p = 0.0342) were observed with the growing expression level of let-7d. Cisplatin, 5-FU
and doxorubicin caused similar decreased of cell survival with the increase of let-7d level
(p = 0.004, post-trend p = 0.046; p = 0.004, post trend p = 0.0005 and p<0.0001, post trend
p = 0.0001, respectively). All models were resistant to paclitaxel, irrespective of let-7d
expression levels. Only two of the generated models (A and C) were radiosensitive
(p = 0.0002). Conclusion: the above results indicated that the level of let-7d expression is
an important factor for cell response to irradiation and chemotherapeutics.
Introduction
Hypopharynx cancer is an uncommon cancer of the head and neck area. It occurs both in
males and females, primarily aged between 50 and 60 years. In most cases, hypopharyngeal
cancer is of a mucosal squamous cell origin, preceded by various precancerous lesions.
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Hypopharyngeal cancer does not usually have early symptoms, along with a high ability to
metastasize, thus causing the lowest survival rate of all head and neck cancers. The treatment
approach is based on surgery and postoperative radiotherapy. These advanced, unresectable
cancers are treated by radiation and/or chemotherapy. Personalization of therapy might
improve patients’ survival, but it is necessary to find biomarkers describing radio- and chemo-
sensitivity for this kind of tumor. One promising group of biomarkers is miRNAs.
In addition, miRNAs are about 22 nucleotides long, with non-coding RNAs being well-
known [1]. The miRNA precursors are transcribed from the genome (pri-miRNA) and create
immature forms of miRNA called pre-miRNA—which are transformed to about 22 nt
duplexes by Drosha and Dicer enzymes. One of the duplex strands, the guide strand, was
incorporated into the RISC complex, which usually binds to 3’UTR region of target mRNA
[2–4]. miRNAs can regulate from 30–60% of human genes [5]. Some data suggest that second
strand, miRNA, takes part in the regulation of gene expression [6]. These small RNAs are
associated with cell cycle, apoptosis, proliferation, differentiation, metabolic pathways, and cell
response to various stressors [7–12]. Half of the known miRNA genes are located close to or
inside chromosome regions, usually mutated in cancer [13,14], which are fragile, unstable, and
have cancer-associated sites. Single miRNAs function as tumor suppressors, oncogenes (onco-
miRs) or has dual functions [15–20].
Lethal-7d (let-7d) is a member of the let-7 family, playing a critical role in the regulation of
development and carcinogenesis. This family is conserved across species and is considered to
be ancient [21]. Let-7 miRNAs are the most abundant among all miRNAs [22]. The let-7 fam-
ily is involved in many cellular processes, having an important impact in cancer formation,
progression, and metastasis. The family acts as tumor suppressor miRNA, and regulates
expression of many oncogenes by both direct and indirect pathways [23–27]. The overall
expression of let-7 family members decreases in human cancers and stem cells, but also have
high expression levels in some cases [28]. The expression of let-7 is deregulated in cancers
such as: pancreatic, prostate, primary pigmented nodular adrenal dysplasia, head and neck,
ovarian, breast, bladder, kidney, and retinoblastoma [29–37]. The implication of the let-7 fam-
ily in cancer is multifaceted; it regulates cell-cycle, apoptosis pathways, chemo- and radiosensi-
tivity of the cell, as well as influences on tumor-initiating cells (TICs) formation and epithelial-
to-mesenchymal transition process (EMT) [38–41].
This study is based on our observation that in some cases of head and neck squamous cell
carcinoma (HNSCC), let-7d is upregulated in tumor tissue [42]. In this work, we tried to




The FaDu cell line and its variants were maintained in Dulbecco’s Modified Eagle Medium
(DMEM) with high glucose (4.5 g/L, Sigma), supplemented with 8.85% (v/v) of fetal bovine
serum (Sigma), 1.77 mM L-glutamine (PAA), 0.885% (v/v) MEM non-essential amino acid
solution (PAA), 0.885% (v/v) penicillin-streptomicin (PAA), and 8.85 mM HEPES (Sigma).
The 293T cell line used for the production of lentiviral vectors was cultured in DMEM with
high glucose (4.5 g/L) medium (Sigma) supplemented with 8.85% (v/v) fetal bovine serum
(Sigma) and 20 mg gentamicin (Kirka). Cell lines were cultivated in a humidified 5% CO2
atmosphere at 37˚C. The mycoplasma detection tests (Minerva) were performed routinely
during cell line culturing. All cells used in the experiments were the same ones used in the 15th
splitting.
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Constructs designing, plasmids production, and lentiviral transduction
The let-7d gene sequence and its flanking sequences (about 180 nucleotides) were amplified by
the PCR method using two pairs of primers: F1: 5’CAATTTAAATGTCATATGGCCAGATA and
R1: 5’CATTAATTAAAGTTATCAATGTCAGCA; F2: 5’TCACTCGAGGTCATATGGCCAGATA,
and R2: 5’TCACTCGAGAGTTATCAATGTCAGCA (two different pairs of primers to achieve
single and double let-7d cassettes). Purified inserts were cloned into pWPXL-GFP plasmids
between PacI and SwaI sites. The obtained plasmids were sequenced to verify the correctness
of amplified inserts. Lentiviral particles were generated by cotransfecting 20 μg of lentiviral
vectors (pWPXL-7d, pWPXL-7d-7d, pWPXL-GFP), 15 μg of p89.1 and 7 μg of pMD2G of
packing vectors in 293T cells using the CaCl2/HBS method. FaDu-7d, FaDu-7d-7d, and FaDu-
GFP cell line models were achieved through lentiviral infection at the single and multiple
infection sites (maximum 3 times). The clonal selection was performed.
Characterization of cell line models
The miRNA expression levels. The total RNA from cell line models with different levels
of let-7d expression was isolated using the TRI Reagent (Sigma). The miRNA levels were
defined by a two-step qRT-PCR method, using TaqMan microRNA Assay (Applied Biosys-
tems, Foster City, CA, USA). Data obtained were compared to FaDu-GFP cell lines and calcu-
lated with the 2-ΔΔCt method. The snoRNA U18 was used as an internal control.
Proliferation. The proliferation ratio of cell line models was measured by 3-H thymidine
incorporation assay. 7000 cells per well in 96-well dishes were seeded. After 48 h of incubation,
the 3-H thymidine was added. Incorporation into DNA was measured with a scintillation
counter (MicroBeta PerkinElmer, Waltham, MA, USA) and compared to the FaDu-GFP cell
line.
The qRT-PCR of selected genes. The qRT-PCR primers for genes involving pluripotency
(OCT3/4, SOX2, NANOG), chemo-, radio-resistance/apoptosis (ATM, ABCB1, BAX,
CASPASE3, BCL2) and let-7d targets (DICER, HMGA1/2, MYC, H-RAS, K-RAS, N-RAS,
ARID3A) were designed with the Universal ProbeLibrary Assay Design Center (Roche
Applied Science, Basel, CH). The reverse transcription PCR was performed using the iScript
cDNA synthesis kit (Bio-Rad, Berkeley, CA, USA) while the qRT-PCR was performed with the
2x SYBR Green master mix (Roche, Basel, CH) and Light Cycler 96. Results were calculated
with the 2-ΔCt method. The GAPDH gene was used as a reference, and melting curves discrimi-
nated non-specific products of PCR reactions. Each experiment was repeated at least 3 times.
Response to irradiation
Cell line irradiation experiments were performed by the Medical Physics Department. Cells
were irradiated on a Varian Clinac 2300 linear accelerator. The cells were irradiated in a special
water phantom MP1 (PTW, Freiburg, GY) with 6 MV accelerating potential.
Clonogenic assay. The cells were seeded in 25 cm2 culture flasks, which were filled up
with PBS, and were irradiated using a dose of 2 Gy. Following that, irradiated and control
(non-irradiated) cells were seeded in 6-well plates. The cells were cultivated for 10–14 days.
Next, the colonies were stained and counted.
Response to chemoexposure
IC50. The IC50 of cisplatin, 5-FU, doxorubicin, and paclitaxel for the FaDu cell line was
defined using the MTT assay.
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MTT assay. 7000 cells per well of cell line models were seeded in 96-well plates. The IC50
concentration of drugs was added and incubated for 48 h with cells. The results for samples
treated with the drug were compared to those without drug treatment, as well as being com-
pared to control (FaDu-GFP) line.
Statistical methods
Statistical analysis was performed with the use of Prism v. 4.0 (GraphPad Software, San Diego,
CA, USA). All experimental values were obtained in at least three independent experiments
and presented on average with standard deviation error bars. A two-tailed p< 0.05 was
considered to represent a statistically significant result. The different types of variables (i.e.,
expression level of let-7d; expression levels of pluripotency, drug resistance biomarkers; prolif-
eration; irradiation, and chemoexposure response) were measured in subsequent A-E cell lines
with different levels of let-7d expression; these were analyzed using one-way analysis of vari-
ance (the ANOVA test) with either a post-test for trend or a comparison of each cell line to the
control. The Bonferroni correction was used for estimation of post-test significance.
Results
Characteristics of the FaDu/let-7d cell line models
Different levels of let-7d expression have been achieved using the lentiviral system. The modi-
fied cells were chosen using a clonal selection method, in order to achieve a cell line with a
“mother” genetic background. The main limitation of this experimental approach is the unpre-
dictable position of the lentiviral integration: this may affect the expression of neighboring
genes. Nevertheless, this system is considered safe and is commonly used for RNAi experi-
ments, as well as for induced pluripotent stem cell (IPS) production. To verify that the side-
effects of lentivirus did not affect cell response, we compared cells with single and double cas-
settes of let-7d. Two FaDu cell lines were created with a single cassette of let-7d (FaDu-7d) and
with a double cassette of let-7d (FaDu-7d7d). The second one was generated with the use of
half amount of lentivirus with the double let-7d construct for transfection. The FACS analysis
of GFP confirmed that FaDu-7d7d contained twice less amount of virus particles. The expres-
sion level of let-7d in the both lines was the same, what was reflected with the same behavior
after irradiation, (Fig 1A). Experimental results allowed us to conclude that observed effects
were caused by let-7d.
Using the lentiviral system and the single clone selection method, six cell line models (A,
B, C, D, E, and reference FaDu-GFP) were obtained. The expression level of let-7d for each
model was calculated, compared to the FaDu-GFP cell line. The following results were
obtained: A: 8.72; B: 17.44; C: 22.85; D:37.93, and E: 57.89. The flow cytometry analysis of the
GFP marker showed high homogeneity (over 97% of FITC-H) of positive cells compared to
non-transduced FaDu cells (Fig 1A). Models differed from each other by the expression level
of let-7d, such that these differences were statistically significant (p< 0.0001). Models were
ordered from A with the lowest level of let-7d to E as the highest one; in this composition of
let-7d expression, a linear trend was shown (p< 0.0001) in Fig 1B. The proliferation ratio gen-
erally decreased in overexpressed let-7d cell lines, compared to the control FaDu-GFP line (Fig
1C), but differences between models were not statistically significant (p = 0.3739) and a trend
in groups was not observed (p = 0.2379). Although model D seemed to behave differently from
the others the difference is not statistically significant and therefore the most likely it does not
result from biological features.
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Influence of different levels of let-7d on expression of selected genes
There were no differences among models for OCT3/4, SOX2 and NANOG mRNAs expression
(Fig 2A). Analysis of let-7d mRNA targets revealed statistically significant differences in
expression among models for K-RAS (p = 0.0369), without a trend and for CASPASE3
(p = 0.0342; post-trend p = 0.0675). Other let-7d targets mRNA did not show statistically sig-
nificant differences (Fig 2B). In the group of analyzed mRNAs connected with chemo-radiore-
sistance/apoptosis, differences in the expression among models, we observed for BAX
p = 0.0111 (but not trend p = 0.344) and ATM p = 0.0506 (but not trend p = 0.203). For
ABCB1 expression, differences among models were not statistically significant (p = 0.2029) but
a decreasing trend of expression was observed in the group of models (p = 0.034). Expression
level of BCL2 did not differ among the analyzed models. This part of the analysis was presented
in Fig 2C. Summarized results showed that model B differed from the others, due to overex-
pression in nearly all studied mRNAs. Model E demonstrated the lowest expression of all ana-
lyzed mRNAs. This can exclude model A from statistical analysis. Models B-E showed
statistically significant differences among the models for CASPASE3 (p = 0.01), ATM
(p = 0.044), and positive trends for most analyzed mRNAs: CASPASE3 (p = 0.0017), ATM
(p = 0.0090), K-RAS (p = 0.0497), N-RAS (p = 0.0364), HMGA1 (p = 0.0414), and ARID3A
(p = 0.0367). It must be noted that although expression of most genes does not show a signifi-
cant trend (due to high levels between-model variation) when we observe almost all cases, the
expression of analyzed genes decreases with increasing levels of let-7d (value of the slope and
correlation coefficient R is almost always< 0). We expected that increased expression of let-
Fig 1. Characteristics of cell line models. A) The FaDu cell line has been transduced using two different lentiviral constructs, containing single
and double cassettes of let-7d. The let-7d expression levels were similar, but the MEAN of GFP fluorescence marker was nearly half lower in the
7d7d line than in 7d. The irradiation effect in both cases was similar. B) Five cell line models based on the FaDu cell line have been stable for
further experiments. The expression for each model was calculated, comparing it to the FaDu-GFP cell line, using the 2-ΔΔCt method. The
following results were found: A: 8.72; B: 17.44; C22.85; D:37.93, and E:57.89; C) the proliferation ratio generally decreased in the
overexpressed let-7d cell line, compared to the controls for the FaDu-GFP line; however, differences between models were not statistically
significant, and as such, we did not observe a trend.
https://doi.org/10.1371/journal.pone.0180265.g001
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7d (A-E) would show decreased expression of mRNAs. This indicates the expected let-7d’s
expression of all studied genes; however, the effect was too small, while the experimental vari-
ety was too large, yielding no statistical significance for the individual gene. Data is presented
in Fig 2D.
Response of FaDu models to cisplatin, 5-FU, paclitaxel, and doxorubicin
The cell line models (A-E) were exposed to chemotherapeutics used in HNSCC treatment. The
IC50 dose was established using the non-modified FaDu cell line and was as follows: 1.12 μg/
mL for cisplatin; 0.86 μg/mL for 5-FU; 0.54 μM for paclitaxel, and 0.06 μM for doxorubicin.
Cisplatin, 5-FU and doxorubicin caused a reduction of the proliferation ratio in all models.
Cisplatin decreased cell survival by about 20% compared to control in FaDu-GFP (with the
exception of model B). The difference in cell survival among models was statistically significant
(p = 0.0014) and a linear trend was also observed (p = 0.0460). We noted that 5-FU also caused
a decrease of cell survival (except in model B). Differences in cell survival among models were
statistically significant (p = 0.004) and the linear trend was present (p = 0.0005). Similar results
were obtained for doxorubicin, which generally caused reduction of cell survival (except in
model E). Differences among models were statistically significant (p< 0.0001), as we observed
a linear trend (p< 0.0001). Models B and E demonstrated a different response to chemothera-
peutics. Model B was resistant to cisplatin and 5-FU. Model E was resistant to Doxorubicin.
Contrary to the above chemotherapeutics, paclitaxel caused about 40% higher cell survival in
comparison to the control in FaDu-GFP, without differences among models (p = 0.1484) or
linear trends (p = 0.7651). All models were resistant to paclitaxel irrespective of let-7d expres-
sion level. Experimental results are summarized in Fig 3A.
Fig 2. Expression of genes characteristic for. A) pluripotency (OCT3/4, SOX2, NANOG) and B) let-7d targets: K-RAS, Caspase3, H-RAS, N-RAS,
HMGA1, HMGA2, C-MYC, ARIDA3A, DICER; C) genes connected with chemo-radioresistance/apoptosis (BAX, ATM, ABCB1, BCL2); D) statistical
analysis of models B-E indicated positive results for mRNAs: Caspase3, ATM, K-RAS, N-RAS, HMGA1, and ARID3A.
https://doi.org/10.1371/journal.pone.0180265.g002
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Response of FaDu models to irradiation (IR)
The cell line models were irradiated by a dose of 2 Gy, culturing 10–14 days, at which point the
survival fraction (SF) was calculated. The results for each model were as follows: A—30.71%; B
—54.33%; C—36.67%; D—71.36%; E—59.81%, and FaDu-GFP—60.08%. The differences in
survival fraction were statistically significant (p = 0.0002) only for models A and C. The linear
trend was not observed. Experimental data is summarized in Fig 3B.
Fig 3. Response of FaDu let-7d models to chemo-and radiotherapy. A) The cell line models (A-E) were exposed to chemotherapeutics: cisplatin
(1.12 μg/mL); 5-FU (0.86 μg/mL); paclitaxel (0.54 μM), and doxorubicin (0.06 μM) were compared to FaDu-GFP B) Survival fractions [SF%] of the cell
models were assessed according to a dose of 2 Gy. The differences in survival were statistical significant (p = 0.0002) for the models A and C.
https://doi.org/10.1371/journal.pone.0180265.g003
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Discussion
The role of let-7 in cancer development and diagnostics has already been described. Currently,
it is considered to be a therapeutic application, based on the restoration of the normal let-7
level. This approach is recommended for those particular cancers, which show underexpres-
sion of miRNA. On the other hand, let-7 may be also be overexpressed, which indicates that
let-7 does not play an only suppressor function, but can also act as oncomiR. This notion,
among others, was supported by experiments on liver cells showing that chronic overexpres-
sion of let-7 caused liver damage, degeneration, and finally cancer [43]. Overexpression of let-
7 may be induced by different mechanisms: from regulation of let-7 cluster transcription via
changes in maturation machinery to global deregulation of cell pathways. Firstly, the effect of
overexpressed let-7d was showed by Chang et al [44] demonstrating that let-7d negatively
modulated TWIST and SNAIL expression. However, target mRNA analysis in this work
revealed statistically significant result only for K-RAS and CASPASE3. It may be assumed that
a lack of substantial changes in expression levels of studied mRNAs was caused by high levels
between-model variation. On the other hand, in most cases, we observed a negative or close to
0 slope, which suggested that different let-7d levels inhibited expression of the examined
mRNAs. Another explanation of our results relates to the very low level of let-7d expression in
FaDu cells, in fact, generated expression of let-7d in the models was still too low to see substan-
tial changes in analyzed mRNA expression. This notion is in line with the observation that
when model A was excluded, a statistically significant trend was observed for CASPASE3,
ATM, K-RAS, N-RAS, HMGA1, and ARID3A. This may suggest that more noticeable differ-
ences for the investigated genes expression may be observed for higher levels of let-7d than
presented in model A and the effect of let-7d overexpression ought to be analyzed in models
with its expression higher than in model E. Thirdly, let-7d belongs to the family including 10–
13 members [27], sharing common mRNAs targets but having their own specific characteris-
tics. Some authors postulate that the overall level of the let-7 family is important for its biologi-
cal effect [45]. We analyzed the influence of let-7d expression, but it is possible that not all of
its levels harmonized with those of other members of the family. The specific FaDu genetic
context influenced our data.
Cell response to chemo- and radioexposure
The main question of this study is how different expression levels of let-7d affect sensitivity to
chemo- and radiotherapy. Tumor resistance to chemotherapeutic drugs is the result of deregu-
lation of various cell mechanisms, such that finding the biomarker of chemosensitivity for this
group of drugs is a real challenge. On the other hand, loss of rerelet-7 family, in particular, has
been correlated with drug resistance in many tumor types, as well as maintenance of an appro-
priate expression level (correlated to successful chemotherapy). In the case of patients with
esophageal cancer, let-7b and let-7c were used as indicators of sensitivity to cisplatin [46]. Let-
7 affected esophageal squamous cells by regulating IL-6/STAT3 pathway so that the designa-
tion of let-7b/c expression level was useful in treatment choice [46]. The influence of overex-
pressed let-7d on chemoresistance has been less examined. In the above-cited work [44],
authors observed that overexpressed let-7d inhibited chemoresistance to cisplatin and pacli-
taxel in OSCC-ALDH1+ cells; this observation was correlated with downregulation of the mul-
tidrug resistance (MDR) gene. Our experiments showed that with the exception of model B
increasing expression of let-7d has influenced on response to cisplatin (with a linear trend).
Additionally, a decreasing trend of ABCB1 expression was observed. Similar results were
obtained for 5-FU and doxorubicin. Model B was resistant to both Cisplatin and 5-FU,
whereas model E was resistant to Doxorubicin, which suggested that despite the noticed linear
FaDu cell line as response model to chemo- and radiotherapy for levels of let-7d expression
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trend, not each overexpression level of let-7d was sensitized to chemotherapeutics. To explain
in more details above results we analyzed expression levels of targets/apoptosis/chemoresis-
tance genes but the list of mRNAs showing statistically significant differences among models
in expression levels was very short (CASPASE3, BAX, and ATM, slop for ABCB1). In sub-
group containing models B-E decreased expression level was noticed for CASPASE3, ATM,
and HMGA1. Involvement of these molecules in chemo-resistant/sensitivity was documented.
It is possible that let-7d influences sensitivity to chemotherapeutics both by regulating (direct
or indirect) of the genes connecting with apoptosis and by repressing the genes promoting
self-renewal/TIC formation. Based on this limited number of analyzed mRNAs our explana-
tion has speculative character. FaDu is described as an aggressive cell line, therefore, its tran-
scriptome needs for explanation real influence of let-7d as well as experiment with paclitaxel.
Paclitaxel caused a nearly 40% higher cell survival compared to the control arm of FaDu,
which did not depend on let-7d level. This might be connected with specific FaDu cells in
genetic disorders.
In experiments with irradiation, statistically significant differences in survival fraction
were obtained only for models A and C. Generally, let-7 family is overexpressed in radiosen-
sitive cancer cells with the exception of let-7g, which overexpression was associated with
radioresistance. It was also postulated that let-7 radiosensitized cells via regulation of the
RAS family [47, 48]. This idea was experimentally confirmed by Oh et al regarding human
pancreatic (ASPC1) and lung tumor (A549) cell lines [48]. The authors demonstrated that
overexpression of let-7a led to downregulation of K-RAS, creating radiosensitivity of investi-
gated cell lines. Even though the higher let-7 expression is connected to a radiosensitive phe-
notype after irradiation, let-7 expression decreased [49]. The mechanism of this process is
not clear, although it probably involved other molecules controlling cellular response to IR
(in the case of let-7a and let-7b, in which expression was reduced by wild type p53) [49].
Looking for radiosensitivity in the miRNA signature for HNSCC patients, Liu et al [50] vali-
dated data obtained from in vitro experiments by analyzing patient samples in the TCGA
base. Patients with a complete response were characterized by upregulation of miR-16, miR-
29b, miR-150, miR-1254, and down-regulation of let-7e after irradiation. Additionally, ATM
expression levels were lower, compared to those in resistant patients. In our experiments,
only two models responded to irradiation, but we did not find an explanation about why this
phenomenon took place. It should be indicated that the FaDu cell line is known to have
mutations in CDKN2A (c.151-1G>T), SMAD4 (c.1 1659del1659), TP53 (c376-1G>A;
c.743G>T) genes. It is possible that changes in p53 caused that effect of certain levels of the
let-7d effect to be more visible. However, we concluded that the level of the let-7d expression
affected the IR response.
Conclusion
The determination of individual miRNA expression changes can be an important marker of
successful patient treatment. We focused on let-7d, known as miRNA suppressor molecule,
for which overexpression was described in HNSCC. In other studies both over and underex-
pression of let-7d in different cancer types were also observed. In fact, the actual level of let-7d
differ substantially between cancer samples and cannot be simply classified either as a high
(overexpression) or low (underexpression). Therefore in our study, we focused on the ques-
tion, whether incrementally different levels of let-7d influence chemo- and radiosensitivity.
Generally, increased levels of let-7d enhanced cells sensitivity to chemotherapeutics. Only two
of the investigated models showed an effect after irradiation. On the other hand, growing level
of let-7d expression caused a declining tendency in the expression of the studied genes but it
FaDu cell line as response model to chemo- and radiotherapy for levels of let-7d expression
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does not let to connect these specific radio- and chemoresistant let-7d levels with changes of
expression of investigated mRNAs. Summarizing, we found that level of let-7d was of signifi-
cance for cell response to irradiation and chemotherapeutics.
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